XRCC5 Antibody

What is XRCC5/Ku80 and what is its primary function in cellular processes?

XRCC5/Ku80 is an 86 kDa nuclear protein that forms a heterodimer with Ku70 (XRCC6) to create the Ku complex. This complex plays a crucial role in the non-homologous end joining (NHEJ) pathway of DNA double-strand break repair. Recent research has expanded our understanding of XRCC5 beyond its canonical DNA repair function, revealing its involvement in transcriptional regulation of genes such as human telomerase reverse transcriptase (hTERT) . XRCC5 contains domains responsible for DNA binding, dimerization with Ku70, and interactions with other proteins in the DNA repair machinery. In normal cells, XRCC5 primarily localizes to the nucleus, which can be visualized using immunohistochemistry techniques with appropriate XRCC5 antibodies .

What epitopes do commercial XRCC5 antibodies typically target?

Commercial XRCC5 antibodies target various epitopes depending on the intended application. For instance, the Human Ku80/XRCC5 Antibody (AF5619) targets the Asn402-Lys565 region of recombinant human Ku80 . Another antibody targets amino acids 543-732 of human Ku80 . The selection of epitope is critical as it affects antibody specificity and functionality across different applications. When epitopes are in highly conserved regions, antibodies may cross-react with XRCC5 from multiple species, as seen with the rabbit polyclonal antibody that reacts with human, mouse, and rat XRCC5 . Researchers should select antibodies with epitopes that do not interfere with protein-protein interactions they wish to study.

How can researchers validate the specificity of XRCC5 antibodies?

Validating antibody specificity is essential for reliable research outcomes. A multi-approach validation protocol includes:

• Western Blot analysis: Using lysates from cell lines known to express XRCC5 (e.g., 293T, A549, Jurkat) should reveal a specific band at approximately 86 kDa . Multiple cell lines should be tested to ensure consistent detection.

• Positive and negative controls: Include cell lines with high XRCC5 expression as positive controls and XRCC5-knockdown cells as negative controls.

• Immunoprecipitation followed by mass spectrometry: This confirms that the antibody specifically pulls down XRCC5 and identifies any cross-reactive proteins.

• Immunohistochemistry patterns: XRCC5 antibodies should show predominant nuclear staining, as demonstrated in human breast cancer tissue samples .

• Blocking peptide competition: Pre-incubation of the antibody with the immunizing peptide should eliminate specific staining.

Using these validation approaches ensures experimental reproducibility and reliability of research findings.

How can XRCC5 antibodies be employed to investigate the XRCC5-hTERT transcriptional axis in cancer?

Recent discoveries have identified XRCC5 as a novel hTERT promoter-binding protein, establishing a critical XRCC5/NRF2/hTERT signaling axis in hepatocellular carcinoma (HCC) . Researchers can employ XRCC5 antibodies to investigate this pathway through:

• Chromatin Immunoprecipitation (ChIP) assays: XRCC5 antibodies can be used to demonstrate the association of XRCC5 with the endogenous hTERT promoter in cancer cells. Studies have shown XRCC5 specifically binds to the region between -144 and -70 bp on the hTERT promoter .

• Biotin-streptavidin-agarose pull-down assays: XRCC5 antibodies can verify the presence of XRCC5 in protein complexes pulled down with biotin-labeled hTERT promoter sequences .

• Co-immunoprecipitation experiments: XRCC5 antibodies can be used to investigate the interaction between XRCC5 and NRF2, which has been shown to be critical for hTERT upregulation .

• Immunohistochemistry of patient samples: Correlating nuclear XRCC5 levels with hTERT expression and patient outcomes provides clinical relevance to the molecular findings .

What are the optimal conditions for XRCC5 antibody use in immunoprecipitation studies?

Successful immunoprecipitation with XRCC5 antibodies requires careful optimization:

For co-immunoprecipitation studies investigating XRCC5 interactions with proteins like NRF2, less stringent lysis conditions (e.g., NP-40 buffer) preserve weak or transient interactions. Pre-clearing the lysate with protein A/G beads reduces non-specific binding. When studying XRCC5-DNA interactions, consider using crosslinking agents before cell lysis to preserve these associations.

How does XRCC5 contribute to chemoresistance, and how can antibodies help study this phenomenon?

XRCC5 has been implicated in chemoresistance, particularly to 5-fluorouracil (5-Fu) in hepatocellular carcinoma. Research indicates that XRCC5 overexpression increases resistance to 5-Fu, while XRCC5 knockdown enhances sensitivity . XRCC5 antibodies can be instrumental in studying this phenomenon through:

• Expression profiling: Western blot analysis with XRCC5 antibodies can quantify XRCC5 levels in chemoresistant versus chemosensitive cells.

• Mechanistic studies: Immunoprecipitation and ChIP assays can reveal how XRCC5 regulates genes involved in drug metabolism and efflux.

• In vivo monitoring: Immunohistochemistry of xenograft tumors from mice treated with chemotherapeutic agents can track changes in XRCC5 expression and localization .

• Clinical correlation: XRCC5 antibodies can be used to stain patient tumor samples before and after chemotherapy to correlate XRCC5 expression with treatment response.

Studies have demonstrated that XRCC5 knockdown significantly increases the sensitivity of HCC cells to 5-Fu both in vitro and in vivo, with corresponding reductions in tumor size, weight, and metastatic potential . Mechanistically, this appears to function through the hTERT signaling pathway, as hTERT overexpression can reverse the sensitizing effects of XRCC5 knockdown .

What are the critical factors for successful Western blot detection of XRCC5?

Optimizing Western blot protocols for XRCC5 detection requires attention to several factors:

• Sample preparation: Nuclear extraction protocols are preferred since XRCC5 is predominantly nuclear. Standard cell lysis buffers may not efficiently extract nuclear proteins.

• Protein amount: Load 20-50 μg of total protein per lane for cell lines with normal XRCC5 expression.

• Antibody dilution: Use XRCC5 antibodies at appropriate dilutions (e.g., 1 μg/mL for AF5619 or 1/500-1/1000 for rabbit polyclonal antibodies ).

• Molecular weight marker: Include markers that clearly identify the 86 kDa region, as XRCC5 appears at approximately this size .

• Reducing conditions: XRCC5 detection has been successful under reducing conditions using appropriate buffer systems .

• Secondary antibody selection: Match to the host species of the primary antibody (e.g., HRP-conjugated Anti-Goat IgG for goat-derived primary antibodies ).

• Positive controls: Include lysates from cell lines known to express XRCC5, such as 293T, A549, or Jurkat human cell lines .

Adherence to these guidelines ensures specific detection of XRCC5 and minimizes background or non-specific signals.

How can researchers optimize immunohistochemistry protocols for XRCC5 detection in tissue samples?

Successful immunohistochemical detection of XRCC5 in tissue samples requires protocol optimization:

• Fixation: Immersion fixed paraffin-embedded sections provide good results for XRCC5 detection .

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) enhances antibody accessibility to XRCC5 epitopes.

• Antibody concentration: Use 1 μg/mL of XRCC5 antibody for optimal staining .

• Incubation conditions: Room temperature incubation for 1 hour provides balanced sensitivity and specificity .

• Detection system: HRP polymer detection systems offer high sensitivity with low background, as demonstrated with Anti-Goat IgG VisUCyte HRP Polymer Antibody .

• Counterstaining: Hematoxylin counterstaining (blue) contrasts well with the DAB (brown) staining of XRCC5 .

• Interpretation: Expect predominantly nuclear staining pattern for XRCC5 .

Using these optimized conditions allows researchers to accurately assess XRCC5 expression in various tissues, including cancer specimens, and correlate expression with clinical parameters.

How does XRCC5 expression correlate with cancer progression and patient outcomes?

XRCC5 expression has significant implications for cancer progression and patient prognosis:

Researchers can use XRCC5 antibodies for immunohistochemical analysis of patient tumor samples to assess XRCC5 expression as a potential biomarker for cancer aggressiveness and treatment response. Combining XRCC5 staining with other markers like hTERT may provide more comprehensive prognostic information than either marker alone.

What experimental approaches can elucidate the functional relationship between XRCC5 and hTERT in cancer cells?

The functional relationship between XRCC5 and hTERT can be investigated through multiple experimental approaches:

• Promoter activity assays: Dual-luciferase reporter constructs containing the hTERT promoter can measure how XRCC5 knockdown or overexpression affects promoter activity .

• Promoter binding region identification: Creating deletion constructs of the hTERT promoter has identified the region between -144 and -70 bp as critical for XRCC5 binding .

• Rescue experiments: Overexpressing hTERT in XRCC5-knockdown cells can determine whether phenotypic effects of XRCC5 depletion are mediated through hTERT .

• In vivo models: Xenograft models with manipulation of both XRCC5 and hTERT expression provide valuable insights into their functional relationship in tumor growth and metastasis .

• Mechanistic interaction studies: Investigating the role of NRF2 as a mediator between XRCC5 and hTERT activation provides deeper insights into the regulatory pathway .

These approaches have revealed that XRCC5-mediated hTERT expression is NRF2-dependent, establishing an XRCC5/NRF2/hTERT signaling axis in HCC that promotes tumor progression and chemoresistance .

How might XRCC5 antibodies be utilized to develop targeted cancer therapies?

The emerging role of XRCC5 in cancer progression suggests several approaches for developing targeted therapies:

• Biomarker identification: XRCC5 antibodies can help identify patient populations most likely to benefit from specific treatments based on XRCC5 expression patterns.

• Therapeutic response monitoring: Serial biopsies analyzed with XRCC5 antibodies can track changes in expression during treatment.

• Drug development: Disrupting the XRCC5/NRF2/hTERT axis could be a promising therapeutic approach, and antibodies can help screen compounds that destabilize this interaction.

• Combination therapies: XRCC5 knockdown increases sensitivity to 5-fluorouracil , suggesting that targeting XRCC5 might enhance conventional chemotherapy efficacy.

• Mechanistic validation: XRCC5 antibodies are essential tools for validating the mechanism of action of any drugs designed to target this pathway.

The discovery that XRCC5 modulates chemosensitivity to 5-Fu through the hTERT signaling pathway provides a foundation for developing novel therapeutic strategies that might overcome chemoresistance in HCC and potentially other cancers with high XRCC5 expression.

What are the emerging applications of XRCC5 antibodies in single-cell analysis techniques?

Single-cell analysis of XRCC5 represents an emerging frontier with several promising applications:

• Cellular heterogeneity: Single-cell imaging with XRCC5 antibodies can reveal heterogeneous expression within tumors, potentially identifying resistant subpopulations.

• Dynamic regulation: Combining XRCC5 antibodies with live-cell imaging techniques can track real-time changes in XRCC5 localization following DNA damage or drug treatment.

• Multi-parameter analysis: Multiplex immunofluorescence incorporating XRCC5 antibodies alongside markers for cell cycle, DNA damage, and other relevant pathways provides contextual information about XRCC5 function.

• Spatial transcriptomics: Correlating XRCC5 protein expression with local gene expression patterns can reveal how XRCC5 influences the tumor microenvironment.

• Mass cytometry: Including XRCC5 antibodies in CyTOF panels enables simultaneous assessment of dozens of proteins in single cells, providing comprehensive phenotyping of cancer cells.

These emerging techniques will provide unprecedented resolution of XRCC5's role in normal and disease states, potentially revealing new functions and regulatory mechanisms not apparent in bulk analysis.